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The development and progression of hypertension dif-fers between men and women. Before menopause, arte-
rial pressure is lower in women than in men of similar age.1 
However, after menopause, this cardioprotection in women is 
lost, and a higher proportion of women than men have hyper-
tension after the age of 65 years.1 Similar differences in arte-
rial pressure control have been observed in other mammalian 
species, including spontaneously hypertensive rats (SHRs).2,3 
These sex-related differences in the development of hyperten-
sion have been strongly linked to sexual dimorphism in the 
renin–angiotensin system (RAS), which plays a pivotal role in 
the long-term regulation of arterial pressure.3,4
Classically, angiotensin II (AngII) acts via the angiotensin 
type 1 receptor (AT1R) to cause vasoconstriction and sodium 
retention. Activation of the pressor RAS is a key mediator in 
the development of hypertension, and drugs that target this sys-
tem are mainstays of current antihypertensive therapy. More 
recently, a depressor arm of the RAS has been recognized, 
which counterbalances the actions of AngII at AT1R. AngII 
together with other biologically active angiotensin peptides, 
including angiotensin (1–7) and angiotensin III, interact with 
angiotensin type 2 receptor (AT2R) to evoke vasodilatation and 
natriuresis. Overwhelming evidence suggests that the depres-
sor RAS is upregulated in women by estrogen, and this con-
tributes to sexual dimorphism in arterial pressure control.3,4 It 
is, therefore, plausible that enhancement of the depressor RAS, 
and in particular the AT2R, may represent a novel therapeutic 
target in the treatment of hypertension, particularly in women.
Our recent data from normotensive rats support the notion 
that AT2R plays an integral, yet sexually dimorphic, functional 
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role in the kidney. Acute systemic blockade of AT2R shifted the 
pressure–natriuresis relationship rightwards in both female and 
male rats.5 Moreover, AT2R blockade blunted the autoregulation 
of renal blood flow (RBF) and glomerular filtration rate (GFR) 
at low renal perfusion pressures and enhanced the renal vaso-
constrictor response to AngII in female rats only.5 This led to 
our conclusion that AT2R modulates sodium excretion in both 
sexes and may contribute to the mechanisms by which female 
sex is protected against AngII-induced vascular alterations and 
hypertension. In addition, we recently demonstrated that acute 
administration of the selective AT2R agonist, compound 21 
(C21), produced significant vasodilatory and natriuretic effects 
in the kidney of both female and male normotensive rats.6 The 
ability of C21 to induce natriuresis was similar between the 
sexes; however, C21 induced a greater increase in RBF in female 
rats. Remarkably, these effects were observed in the absence of 
any AT1R blockade, demonstrating the ability of C21 to directly 
modulate renal function in male and female normotensive rats.6
Despite this evidence for a significant functional role of AT2R 
in the kidney in male and female normotensives, the sex-spe-
cific ability of pharmacological AT2R stimulation to modulate 
renal function in hypertension remains unknown. Therefore, we 
aimed to provide further insight into the ability of pharmacologi-
cal AT2R stimulation using C21 to modulate renal hemodynamic 
and excretory function in hypertension using the SHR model.
Methods
Eighteen- to 19-week-old SHRs were anesthetized and instrumented 
for measurement of mean arterial pressure (MAP; carotid catheter) 
and RBF (transonic flow probe). Renal hemodynamic and excretory 
function was examined in response to vehicle, graded infusion of C21 
(100–300 ng/kg per minute), or C21 combined with the AT2R antago-
nist PD123319 (1 mg/kg bolus plus 1 mg/kg per hour). GFR was 
measured via [3H]-inulin clearance. In a separate cohort of rats, renal 
angiotensin receptor mRNA expression was measured by real-time 
reverse transcription polymerase chain reaction. Detailed methods 
are in the online-only Data Supplement.
Results
Basal Measurements
Body weight and left kidney wet weight did not differ sig-
nificantly between any of the male or female treatment groups 
(Table). Furthermore, uterine weight was similar for each in 
the female treatment groups. The female treatment groups 
also consisted of similar numbers of rats in estrus and anes-
trus, as identified by vaginal smear.
Basal levels of MAP, RBF, and GFR were not significantly 
different between the male and female treatment groups. 
However, although baseline urine flow (UF) and urinary 
sodium excretion (UNa+V) levels did not differ significantly for 
any in the male treatment group, a difference in baseline UF 
and UNa+V was detected between the female C21-treated and 
C21 plus PD123319-treated groups (PGroup<0.01).
Influence of C21 on Renal Hemodynamic Function
In female and male vehicle-treated, C21-treated, and C21 plus 
PD123319-treated SHRs, MAP did not change significantly 
from baseline (Figure 1A and 1D). However, in the male SHR 
treatment group, we observed a small but significant decrease 
(≈7–9 mm Hg) in MAP over time (Figure 1D; PTime<0.001).
In female SHRs, no significant change in RBF was observed in 
response to vehicle treatment. Whereas, in response to C21 infu-
sion, RBF increased significantly from baseline at each dose of 
C21 administered, as compared with the female vehicle-treated 
SHRs (Figure 1B; PGroup<0.001). There was a trend for dose-
dependent increase in RBF in response to C21 in female SHRs 
(PDose=0.066). Furthermore, this renal vasodilatory response to 
C21 in the absence of any change in MAP was reflected by a sig-
nificant reduction in renal vascular resistance, as compared with 
female vehicle-treated SHRs (Figure 1C; PGroup<0.01). Each of 
these responses was completely abolished by coinfusion of C21 
with the AT2R antagonist, PD123319 (Figure 1C; PGroup<0.001 
for RBF; PGroup<0.01 for renal vascular resistance).
Unlike the female SHRs, no significant change in RBF 
was observed in response to C21 in male SHRs. Instead, RBF 
remained close to baseline levels, similar to that observed 
in the male vehicle-treated group (Figure 1E; PGroup>0.05). 
Accordingly, no significant effect of C21 on renal vascular 
resistance in male SHRs was observed (Figure 1F).
Influence of C21 on Renal Excretory Function
Renal excretory function was examined during baseline and 
experimental periods with 300 ng/kg per minute of C21. In 
Table.  Baseline Measurements of Body and Organ Weights, Mean Arterial Pressure, and Renal Function 
in Each Experimental Group
Female Vehicle Female C21
Female C21 Plus 
PD123319 Male Vehicle Male C21
Male C21 Plus 
PD123319
BW, g 208±3 211±2 202±5 330±9 343±5 335±6
KW, g 0.66±0.01 0.67±0.01 0.65±0.01 1.1±0.05 1.1±0.03 1.1±0.04
UW, g 0.37±0.01 0.39±0.03 0.37±0.03 … … …
MAP, mm Hg 168±3 170±3 176±7 190±6 187±4 188±3
RBF, mL/min per g 4.1±0.4 4.7±0.4 5.4±0.4 4.8±0.4 4.6±0.6 4.6±0.5
GFR, mL/min per g 1.5±0.1 1.4±0.1 1.3±0.07 1.1±0.09 1.2±0.03 1.1±0.07
UF, μL/min per g 26.9±6.6 14.15±5.4* 40.1±5.3 15.3±4.7 23.5±3.4 25.6±5.5
U
Na+
V, μmol/min per g 5.6±1.6 2.5±0.9* 8.2±1.5 3.05±1.1 3.9±0.6 4.7±1.1
Data are presented as mean±SEM and were analyzed using ANOVA with Tukey post hoc test. All RBF, GFR, UF, and U
Na+
V values are 
expressed per g of KW. BW indicates body weight; C21, compound 21; GFR, glomerular filtration rate; KW, left kidney wet weight; MAP, 
mean arterial pressure; RBF, renal blood flow; UF, urine flow; U
Na+
V, urinary sodium excretion; and UW, uterine weight.
*P<0.01 vs female C21 plus PD123319-treated rats; n=6 to 9 per group. 
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female SHRs, a time-dependent reduction in GFR was observed 
in response to vehicle treatment. However, a similar reduction in 
GFR was observed in the female C21-treated group (Figure 2). 
Overall, this indicates that there was no significant effect of C21 on 
GFR in female SHRs. Subsequently, there was a greater reduction 
in filtration fraction in female C21-treated versus vehicle-treated 
SHRs (P<0.05; Figure 2). In contrast, because no significant 
change in RBF or GFR was observed in response to C21 in male 
SHRs, no significant difference in filtration fraction was observed 
between male vehicle-treated and C21-treated SHRs (Figure 2).
Finally, no significant change in UF, UNa+V, or fractional 
sodium excretion (FENa+) was observed in either female 
or male SHRs in response to vehicle treatment (Figure 3). 
However, each of these variables increased significantly in 
response to C21 in female SHRs (each PGroup<0.05; Figure 3). 
Importantly, these responses in female SHRs to C21 were 
completely abolished by coinfusion of C21 with PD123319. 
On the contrary, no significant effect of C21 was observed on 
UF, UNa+V, or FENa+ in male SHRs.
Renal angiotensin type 1a receptor, angiotensin type 
1b receptor, and AT2R mRNA Expression
Renal angiotensin type 1a receptor expression was signifi-
cantly greater (≈1.4-fold) in female SHRs as compared with 
male SHRs (P<0.05; Figure 4A). There was no significant 
difference in renal angiotensin type 1b receptor expression 
between male and female SHRs (Figure 4B). Renal AT2R 
expression was also significantly greater (≈4.3-fold) in female 
SHRs as compared with male SHRs (P<0.05; Figure 4C).
A D
B E
C F
Figure 1. Percent change from baseline for mean 
arterial pressure (MAP), renal blood flow (RBF), 
and renal vascular resistance (RVR) in female (A–C) 
and male (D–F) spontaneously hypertensive rats 
(SHRs) in response to 100 to 300 ng/kg per min 
of compound 21 (C21). Data are presented as 
mean±SEM and were analyzed using repeated-
measures ANOVA. **P<0.01, ***P<0.001 vs 
vehicle-treated SHR; ##P<0.01, ###P<0.001 vs 
C21 plus PD123319-treated SHR; n=6 to 9 per 
group. All RBF and RVR values are expressed per 
g of left kidney wet weight.
Figure 2. Percent change from baseline for glomerular filtration 
rate (GFR) and filtration fraction (FF) in female and male 
spontaneously hypertensive rats (SHRs) in response to 300 
ng/kg per min of compound 21 (C21). Data are presented as 
mean±SEM and were analyzed using an unpaired t test to 
compare differences between vehicle-treated and C21-treated 
SHR and between C21-treated and C21 plus PD123319-treated 
SHR; n=6 to 9 per group. All values are expressed per g of left 
kidney wet weight.
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Discussion
The major findings of this study were that pharmacological 
stimulation of AT2R induced renal vasodilatory and natriuretic 
effects in female SHRs. In contrast, no significant renal vaso-
dilatory or natriuretic response to C21 was observed in male 
SHRs. In addition, we confirmed that renal AT2R mRNA 
expression was significantly greater in female than in male 
SHRs. Together, this knowledge provides a strong rationale for 
subsequent studies to investigate the long-term and sex-specific 
renal functional effects of pharmacological AT2R stimulation 
to establish whether AT2R agonist therapy represents a novel 
therapeutic approach for hypertension, particularly in women.
Given the dominant role of kidneys in the long-term regula-
tion of arterial pressure, the preservation of renal function is 
a major goal in the identification of novel therapeutic targets 
for hypertension. In the current study, C21 induced significant 
renal vasodilatory effects in female SHRs, in the absence of 
any significant change in arterial pressure. These responses 
were completely abolished by AT2R blockade, thus confirm-
ing the role of AT2R in mediating this response while provid-
ing further support for the selectivity of this dose range of C21 
for AT2R. The fact that C21 had no significant effect on arte-
rial pressure yet induced renal vasodilatation in female SHRs 
might reflect greater AT2R expression (or a greater AT2R-to-
AT1R ratio) in the renal vasculature as compared with the 
systemic circulation in female SHRs. Certainly, studies in 
both humans and experimental models have demonstrated a 
functional role for AT2R in numerous vascular territories. This 
includes resistance vessels from the renal, mesenteric, uterine, 
adrenal, coronary, and peripheral circulations, as well as large 
capacitance vessels such as the aorta.7
This observation of a sex-specific renal vascular response to 
C21 in the present study is consistent with our previous obser-
vations in rodents that AT2R plays a greater functional role in 
female than in male renal vasculature, providing protection 
against the vasoconstrictor effects of AngII.5,6,8 Furthermore, 
our data support the notion that differences in the renal response 
to C21 between male and female SHRs is attributable to sex 
differences in renal AT2R expression. We observed significantly 
greater basal AT2R mRNA expression in the kidneys of female 
SHRs as compared with male SHRs, in agreement with the pre-
vious findings of Silva-Antonialli et al.2 In addition, although 
we observed significantly greater renal angiotensin type 1a 
receptor expression in female SHRs as compared with their 
male counterparts, the relative AT2R-to-AT1R ratio was much 
greater in female than in male SHRs, although such sex differ-
ences in basal renal AT1R or AT2R mRNA expression are not 
always reported.9 Overall, it is highly plausible that the lack of 
response to C21 we observed in male SHRs is attributable to 
significantly lower renal expression of AT2R, as compared with 
their female counterparts. Subsequently, the dominant AT1R-
mediated effects of endogenous AngII may mask any AT2R-
mediated vasodilatory responses induced by C21 in male sex. 
Certainly, we have previously shown in conscious male SHRs 
that C21 alone administered >4 hours did not elicit any signifi-
cant effect, at least on arterial pressure. However, when given in 
combination with the AT1R antagonist, candesartan, C21 low-
ered arterial pressure in SHRs,10 which fits with this hypothesis.
Figure 3. Percent change from baseline for 
urine flow (UF), sodium excretion (UNa+V), and 
fractional sodium excretion (FENa+) in female and 
male spontaneously hypertensive rats (SHRs) 
in response to 300 ng/kg per min of compound 
21 (C21). Data are presented as mean±SEM 
and were analyzed using an unpaired t test to 
compare differences between vehicle-treated and 
C21-treated SHRs and between C21-treated and 
C21 plus PD123319-treated SHRs. *P<0.05; n=6 
to 9 per group. All values are expressed per g of 
left kidney wet weight.
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The possibility also exists that high levels of endogenous 
AngII may result in significant AT2R stimulation and thus limit 
an additional vasodilator effect of C21 administration, as sug-
gested recently by Brouwers et al.11 Similar to the present study, 
this group did not identify any significant effect of intravenous 
bolus doses of C21 on RBF in male SHRs,11 which may reflect 
the presence of anesthesia, unlike other studies,10 although AT2R-
mediated vasodilatation occurred in anesthetized female SHRs in 
the current study. Interestingly, during combined angiotensin-con-
verting-enzyme inhibition with captopril to inhibit the endogenous 
production of AngII, Brouwers et al11 reported that C21 induced 
dose-dependent renal vasodilatation in male SHRs in the absence 
of any change in arterial pressure, thus supporting their proposi-
tion that the inhibition of endogenous AngII is required in male 
SHRs for AT2R-mediated vasodilatory responses to be manifest.
In the current study, we also observed significant increases in 
both UF and UNa+V in female SHRs in response to acute C21 
administration. This was observed in the absence of a concomi-
tant increase in GFR, suggesting that AT2R-mediated natriuresis 
induced by C21 in female SHRs was more than likely because of 
changes in the renal tubular reabsorption of sodium, rather than 
intrarenal hemodynamic changes. This ability of C21 to increase 
RBF in the absence of any major change in GFR is similar to 
what we observed previously in male and female normotensive 
rats.6 As discussed in this previous study, there are several pos-
sible mechanisms that could explain no change in GFR while 
RBF increased. First, similar vasodilatory effects of C21 at the 
pre- and postglomerular vessels occurred such that RBF can 
increase in the absence of any change in GFR. Second, given 
the reports that AT2R expression on podocytes contributes to the 
maintenance and function of the glomerular filtration barrier,12 
it is also possible that C21 is able to induce the relaxation of 
podocytes to reduce the surface area available for filtration, thus 
leading to a reduction in GFR. Subsequently, a reduction in glo-
merular capillary ultrafiltration coefficient could counteract any 
AT2R-mediated increases in glomerular capillary pressure, thus 
preventing any significant change in GFR.
On the contrary, we did not observe any significant effect 
of C21 administration on UNa+V in male SHRs. This finding is 
somewhat surprising given that we and others have previously 
reported significant natriuretic effects of AT2R stimulation 
alone in numerous male rodent models, including normoten-
sive Sprague–Dawley rats, uninephrectomized rats, and obese 
Zucker rats.6,13–15 This finding suggests that the lesser renal AT2R 
expression we and others have identified in male versus female 
SHRs may be responsible for the lack of natriuretic response of 
male SHRs to C21 in the present study.2 Moreover, renal AT2R 
expression is likely lesser in male SHRs as compared with these 
other male rodent models in which C21-mediated natriuretic 
effects have been observed. Overall, concomitant blockade of 
AT1R or angiotensin-converting enzyme inhibition may, there-
fore, also be required for AT2R-mediated natriuresis in male 
SHRs to manifest and should be addressed in future studies.
Although our studies demonstrate the ability of acute AT2R 
stimulation to modulate renal function, at least, in female 
SHRs, caution should be applied when interpreting these find-
ings given that they were performed in anesthetized and renal 
denervated animals. Prospective studies should investigate the 
chronic effects of pharmacological AT2R stimulation on renal 
function and arterial pressure control in the hypertensive set-
ting to confirm the physiological significance of this work. 
In addition, in light of the knowledge that the enhancement 
of the depressor RAS in women is modulated by estrogen, it 
will also be important to take into account how aging and age-
related changes in sex hormone balance influence the potential 
of AT2R as a therapeutic target in female and male sexes. This 
is of course essential to the clinical translation of this work 
given that the population most frequently in need of clinical 
treatment for hypertension and associated disease is the elderly 
subjects.4 Certainly, it is highly plausible that the protective 
role of AT2R in the female kidneys is lost with age in associa-
tion with a reduction in estrogen levels, such that menopausal 
status may be a critical factor when it comes to establishing the 
suitability of AT2R as a therapeutic target in women.
It will also be of interest to determine the ability of pharma-
cological AT2R stimulation to improve the efficacy and utility 
of existing RAS-targeted therapies. Certainly, there is signifi-
cant evidence in literature of a biological cross-talk between the 
angiotensin receptors. Human and animal studies have shown that 
AT2R expression is increased during AT1R blockade16–18 and that 
AT2R contributes, at least in part, to the antihypertensive effects 
of angiotensin receptor blockers. For example, Savoia et al18 
reported that peripheral resistance arteries from diabetic hyper-
tensive patients treated with an AT1R antagonist exhibit enhanced 
AT2R expression and associated AT2R-mediated vasodilatation in 
response to AngII. In addition, studies have shown that AT2R acti-
vation reduces AT1R expression and function.16,19 Taken together, 
these findings support the postulate that AT2R stimulation in the 
A
B
C
Figure 4. Relative renal mRNA expression of (A) angiotensin type 
1a receptor (AT1aR), (B) angiotensin type 1b receptor (AT1bR), 
and (C) angiotensin type 2 receptor (AT2R) in female and male 
spontaneously hypertensive rats (SHRs). Data are presented as 
mean±SEM and are expressed relative to the male SHR group; 
n=7 to 8 per group. Data were analyzed using an unpaired t test. 
*P<0.05 vs male SHRs.
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presence of AT1R blockade would likely provide complementary 
therapeutic benefit and potentiate the long-term antihypertensive 
effects of existing angiotensin receptor blockers. Moreover, in the 
context of the present study, it is likely that greater renal vaso-
dilatory and natriuretic effects may be observed in response to 
C21 treatment against a background of AT1R blockade. As pre-
viously mentioned, we have already demonstrated the ability of 
acute C21 administration to reduce arterial pressure in male SHRs 
during simultaneous AT1R blockade, and this was observed to a 
significantly greater extent compared with AT1R blockade alone.10 
However, we are yet to establish the chronic renal functional and 
antihypertensive effects of this combination therapy and whether 
or not these effects are enhanced in females and/or males.
Perspectives
In summary, the present study demonstrates that AT2R stimu-
lation enhances renal vasodilatation and natriuresis in female 
SHRs, without concomitant alterations in GFR. Chronic stud-
ies of AT2R agonist therapy on renal function and arterial 
pressure in hypertensive states are now required to establish 
whether pharmacological stimulation of AT2R with highly 
selective AT2R agonists such as C21 could, therefore, represent 
a suitable therapeutic target for the treatment of hypertension 
and associated renal disease, at least in women. This includes 
investigations into whether AT2R agonist therapy can improve 
the efficacy and utility of existing antihypertensive therapies.
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What Is New?
•	This is the first study to demonstrate the sex-specific ability of pharma-
cological stimulation of angiotensin type 2 receptor (AT
2
R) to modulate 
renal function in hypertension.
What Is Relevant?
•	Acute AT2R stimulation induced renal vasodilatation and increased na-
triuresis in the female spontaneously hypertensive rat kidney. This was 
observed in the absence of any significant change in arterial pressure or 
glomerular filtration rate.
•	No significant effect of acute AT2R stimulation on renal hemodynamic or 
excretory function was observed in male spontaneously hypertensive rats.
•	The sex difference in renal response to C21 may be attributable to sig-
nificantly greater renal AT
2
R mRNA expression in the kidneys of female 
versus male spontaneously hypertensive rats.
Summary
AT
2
R stimulation enhances renal vasodilatation and sodium excretion 
without concomitant alterations in glomerular filtration rate in female 
spontaneously hypertensive rats. Chronic studies of the sex-specific 
effects of AT
2
R agonist therapy in hypertensive states are now required 
to establish the potential of AT
2
R stimulation as a novel therapeutic 
target for the treatment of cardiovascular disease, at least in women.
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Methods 
Animals 
Seventeen-week old male and female spontaneously hypertensive rats (SHR) 
were obtained from the Animal Resources Centre (Perth, WA, Australia). Rats 
were housed under standard laboratory conditions (12-hour light/dark cycle at 
a temperature of 21C) and were fed a sodium-controlled diet (0.25% sodium 
chloride; Specialty Feeds, Glen Forrest, WA, Australia) ad libitum. 
Experiments were approved by the Monash University, School of Biomedical 
Sciences Animal Ethics Committee and were performed in accordance with 
the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes. Rats were allowed 1-2 weeks to acclimatize prior to the 
commencement of the study protocol. 
 
Surgical Procedure 
The rats were surgically prepared as described in detail previously.1 Briefly, 
rats were anesthetized with Inactin (thiobutabarbital; 150 mg/kg 
intraperitoneal injection; Sigma Aldrich, St Louis, Missouri, USA). The left 
carotid artery and jugular vein were catheterized for the continuous recording 
of mean arterial pressure (MAP) and the intravenous infusion of fluid 
replacement (2% BSA ;Sigma Aldrich) and tritiated inulin ([3H]-inulin; Sigma 
Aldrich), respectively. The left kidney was then exposed and denervated and 
the left ureter was catheterized for the collection of timed urine samples. 
Finally, a transit-time ultrasound flow probe (0.7VB; Transonic Systems, 
Ithaca, New York, USA) was positioned around the renal artery for the 
continuous recording of renal blood flow (RBF).  
 
Experimental Procedure 
Following surgery, intravenous infusion of PD123319 (1 mg/kg bolus plus 1 
mg/kg/h; Sigma Aldrich) or vehicle (0.9% saline; 1 ml bolus plus 1 ml/h) began 
and this was continued for the duration of the experiment. After 60 minutes, 
intravenous infusion of constant vehicle or graded doses of C21 (0, 100, 200 
and 300 ng/kg/min) then commenced.  At each dose, a 10-minute 
equilibration period was allowed, followed by 5-minute measurements of RBF. 
In addition, during the baseline and 300 ng/kg/min C21 periods, urine 
produced by the left kidney was collected and corresponding arterial blood 
samples were taken from the left carotid artery at the end of both urine 
collection periods. Upon completion of each experiment, urinary sodium 
excretion (UNa+V) and fractional sodium excretion (FENa+) were measured, as 
previously described.1 Glomerular filtration rate (GFR) was measured based 
on [3H]-inulin clearance. Finally, the left kidney was excised and weighed. In 
addition, the stage of the estrus cycle of each female SHR was also 
determined by a vaginal smear and uterine weight was measured.   
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Renal AT1aR, AT1bR and AT2R expression 
In a separate cohort of rats, kidneys were collected, weighed and snap frozen. 
RNA was extracted from the kidney using the RNeasy Mini kit (Qiagen, 
Doncaster, Victoria, Australia). AT1aR, AT1bR and AT2R mRNA expression 
was analyzed by real-time RT-PCR Realplex software with the Applied 
Biosystems 7900HT Fast RT-PCR system (Applied Biosystems, Life 
Technologies, Australia). Samples were run in triplicate using TaqMan gene 
expression assays (Applied Biosystems) with 18S rRNA as the internal 
housekeeping gene. Reactions were setup on a 384-well PCR plate using an 
automated liquid handler (CAS-1200 liquid handler, Qiagen). Relative 
expression was calculated using the comparative cycle of threshold 
fluorescence (2-∆∆CT) method. 
 
Statistical analyses 
Data are expressed as mean  SEM. To compare differences in baseline 
variables, data were analyzed using an analysis of variance (ANOVA) with 
Tukey’s post-hoc test. Mean arterial pressure, RBF and renal vascular 
resistance (RVR) data were analyzed using repeated-measures ANOVA. To 
compare differences in percent changes in variables at 300 ng/kg/min C21 
from baseline between vehicle-treated and C21-treated rats and C21-treated 
and C21+PD123319-treated rats in each sex, and differences in renal 
angiotensin receptor mRNA expression, data were analyzed using an 
unpaired t-test. P values ≤0.05 were considered statistically significant.  
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